title: Soluble angiogenic factors in patients with acute pancreatitis.
abstract: BACKGROUND
  Angiogenic factors are involved in the physiopathology of several inflammatory diseases and they probably play a role in the pathogenesis of acute pancreatitis (AP).
  
  
  OBJECTIVE
  To investigate if angiogenic factors are elevated in patients with AP, their relationship with severity and clinical evolution of AP, and their use as prognosis markers of AP.
  
  
  METHODS
  A case (25)-control (30) study was carried out. Patients with AP were classified according to severity (using Ranson and Glasgow scores) and according to their clinical evolution (taking into account the development of complications during hospital stay). Platelet-derived growth factor (PDGFBB), angiopoietin-1, angiopoietin-2 (Ang-2), angiopoietin tyrosine-kinase receptor, hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), VEGF tyrosine-kinase receptor 1, and VEGF tyrosine-kinase receptor 2 were determined at 12 hours and then at 5 days after hospitalization.
  
  
  RESULTS
  PDGFBB, Ang-2, angiopoietin tyrosine-kinase receptor, and HGF were significantly higher in cases (P<0.001), and in patients with unfavorable clinical evolution (P<0.001). PDGFBB and HGF were significantly higher in patients with severe AP (P<0.05). To predict unfavorable clinical evolution, PDGFBB, Ang-2, and HGF showed an area under receiver operating characteristic curve of 0.97.
  
  
  CONCLUSIONS
  PDGFBB and HGF are related to severity of AP. These factors along with Ang-2 are related to clinical evolution and are useful in predicting the development of several complications during hospital stay. Therefore, these angiogenic factors could be useful as prognosis markers of AP.
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria Princesa, Madrid, Spain. lauespi@yahoo.es
authors.forename: Laura
authors.initials: L
authors.lastname: Espinosa
authors.forename: Pablo M
authors.initials: PM
authors.lastname: Linares
authors.forename: Alicia
authors.initials: A
authors.lastname: Bejerano
authors.forename: Cristina
authors.initials: C
authors.lastname: Lopez
authors.forename: Argeme
authors.initials: A
authors.lastname: Sanchez
authors.forename: Ricardo
authors.initials: R
authors.lastname: Moreno-Otero
authors.forename: Javier P
authors.initials: JP
authors.lastname: Gisbert
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D043925:Angiogenesis Inducing Agents / Q000097:blood*; D042702:Angiopoietin-2 / Q000097:blood; D000077214:Becaplermin; D016022:Case-Control Studies; D005260:Female; D017228:Hepatocyte Growth Factor / Q000097:blood; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000378:metabolism / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000150:complications / Q000378:metabolism / Q000503:physiopathology*; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D011379:Prognosis; D020574:Proto-Oncogene Proteins c-sis; D012720:Severity of Illness Index; D012995:Solubility
chemical_list: D043925:Angiogenesis Inducing Agents; D042702:Angiopoietin-2; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D000077214:Becaplermin; D017228:Hepatocyte Growth Factor